$25.84
+0.06 (+0.23%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SGP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 observational
Held by 1 tracked-famous manager (MILLENNIUM MANAGEMENT LLC) · FINRA short interest 12.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL CombinationNCT07154810observationalUnmedicated eyes with an IOP Reduction from SGP-SPEC-001 Baseline | — | Active, not recruiting | — | Glaucoma, Cataract, Ocular Hypertension | 23 | 2031-04-14 | in 1,699 d | 2025-09-04 |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)NCT07218796Mean IOP Reduction from Baseline (mmHg)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5% · Device: SpyGlass IOL, Commercial IOL | Cataract, Glaucoma, Ocular Hypertension | 400 | 2029-05-31 | in 1,016 d | 2025-10-20 |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)NCT07218783Mean IOP Reduction from Baseline (mmHg)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5% · Device: SpyGlass IOL, Commercial IOL | Cataract, Glaucoma, Ocular Hypertension | 400 | 2029-03-31 | in 955 d | 2025-10-20 |
| Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular HypertensionNCT07641296Mean IOP change from Baseline (mmHg)Non-randomized · Single-masked · Treatment | Phase 1 | Not yet recruiting | Drug: BIM-DRS Low Dose, BIM-DRS High Dose · Device: SpyGlass IOL with silicone pads (no drug) | Glaucoma, Ocular Hypertension | 24 | 2027-02-28 | in 193 d | 2026-06-11 |
| Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionNCT06120842Mean IOP Reduction from Baseline (mmHg)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5% · Device: Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL | Cataract, Glaucoma, Ocular Hypertension | 201 | 2025-01-31actual | — | 2025-08-22 |
| Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle GlaucomaNCT07154797Unmedicated eyes with IOP reduction of ≥20% from Baseline to the Month 6Non-randomized · Single-masked · Treatment | Not applicable | Completed | Combination product: Bimatoprost Implant System / IOL Combination | Cataract, Ocular Hypertension, Glaucoma | 24 | 2022-12-13actual | — | 2025-09-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19